161 related articles for article (PubMed ID: 34638406)
21. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.
Thompson PA; Srivastava J; Peterson C; Strati P; Jorgensen JL; Hether T; Keating MJ; O'Brien SM; Ferrajoli A; Burger JA; Estrov Z; Jain N; Wierda WG
Blood; 2019 Nov; 134(22):1951-1959. PubMed ID: 31537528
[TBL] [Abstract][Full Text] [Related]
22. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
Ciudad J; Orfao A; Vidriales B; Macedo A; Martínez A; González M; López-Berges MC; Valverde B; San Miguel JF
Haematologica; 1998 Dec; 83(12):1069-75. PubMed ID: 9949623
[TBL] [Abstract][Full Text] [Related]
23. Case series: MRD negativity assessment using
Ngai C; Kumar S; Chi-Lai Ho G; Chen S; Chim CS
Ther Adv Hematol; 2021; 12():20406207211030369. PubMed ID: 34616538
[TBL] [Abstract][Full Text] [Related]
24. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma.
Fenk R; Ak M; Kobbe G; Steidl U; Arnold C; Korthals M; Hünerlitürkoglu A; Rohr UP; Kliszewski S; Bernhardt A; Haas R; Kronenwett R
Haematologica; 2004 May; 89(5):557-66. PubMed ID: 15136219
[TBL] [Abstract][Full Text] [Related]
25. Enrichment of circulating myeloma cells by immunomagnetic beads combined with flow cytometry for monitoring minimal residual disease and relapse in patients with multiple myeloma.
Wang N; Tesfaluul N; Li J; Gao X; Liu S; Yue B
Ann Hematol; 2019 Dec; 98(12):2769-2780. PubMed ID: 31748925
[TBL] [Abstract][Full Text] [Related]
26. Quantification of nucleated cells, CD34-positive cells and CFU-GM colonies in single bone marrow samples and bone marrow harvests derived from healthy children.
Schündeln MM; Walde G; Basu O; Havers W; Kremens B
Pediatr Hematol Oncol; 2014 May; 31(4):340-8. PubMed ID: 24498921
[TBL] [Abstract][Full Text] [Related]
27. Minimal residual disease in high-risk neuroblastoma shows a dynamic and disease burden-dependent correlation between bone marrow and peripheral blood.
Lin KS; Uemura S; Thwin KKM; Nakatani N; Ishida T; Yamamoto N; Tamura A; Saito A; Mori T; Hasegawa D; Kosaka Y; Nino N; Nagano C; Takafuji S; Iijima K; Nishimura N
Transl Oncol; 2021 Aug; 14(8):101019. PubMed ID: 33993097
[TBL] [Abstract][Full Text] [Related]
28. [Clinical research on clearance of leukemic cell during induction of remission therapy in children with precursor B cell acute lymphoblastic leukemia].
Yi ZG; Cui L; Gao C; Jin M; Zhang RD; Li ZG; Wu MY
Zhonghua Er Ke Za Zhi; 2011 Mar; 49(3):170-4. PubMed ID: 21575363
[TBL] [Abstract][Full Text] [Related]
29. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
Gambella M; Omedé P; Spada S; Muccio VE; Gilestro M; Saraci E; Grammatico S; Larocca A; Conticello C; Bernardini A; Gamberi B; Troia R; Liberati AM; Offidani M; Rocci A; Palumbo A; Cavo M; Sonneveld P; Boccadoro M; Oliva S
Cancer; 2019 Mar; 125(5):750-760. PubMed ID: 30561775
[TBL] [Abstract][Full Text] [Related]
30. Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.
Schumich A; Maurer-Granofszky M; Attarbaschi A; Pötschger U; Buldini B; Gaipa G; Karawajew L; Printz D; Ratei R; Conter V; Schrappe M; Mann G; Basso G; Dworzak MN;
Pediatr Blood Cancer; 2019 May; 66(5):e27590. PubMed ID: 30561169
[TBL] [Abstract][Full Text] [Related]
31. The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter.
Korthals M; Sehnke N; Kronenwett R; Bruns I; Mau J; Zohren F; Haas R; Kobbe G; Fenk R
Biol Blood Marrow Transplant; 2012 Mar; 18(3):423-431.e3. PubMed ID: 21745451
[TBL] [Abstract][Full Text] [Related]
32. [Role of minimal residual disease detection by multiparameter flow cytometry in newly diagnosed multiple myeloma: an analysis of 106 patients].
Deng SH; Xu Y; Sui WW; Wang HJ; Li ZJ; Wang TY; Liu W; Huang WY; Lyu R; Li J; Fu MW; Zou DH; An G; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):376-381. PubMed ID: 29779345
[No Abstract] [Full Text] [Related]
33. Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia.
Terwijn M; Kelder A; Snel AN; Rutten AP; Scholten WJ; Oussoren YJ; Van De Loosdrecht AA; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
Int J Lab Hematol; 2012 Aug; 34(4):432-41. PubMed ID: 22471741
[TBL] [Abstract][Full Text] [Related]
34. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.
Korthals M; Sehnke N; Kronenwett R; Schroeder T; Strapatsas T; Kobbe G; Haas R; Fenk R
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1109-15. PubMed ID: 23644045
[TBL] [Abstract][Full Text] [Related]
35. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
García-Marco JA; Jiménez JL; Recasens V; Zarzoso MF; González-Barca E; De Marcos NS; Ramírez MJ; Parraga FJP; Yañez L; De La Serna Torroba J; Malo MDG; Ariznavarreta GD; Persona EP; Guinaldo MAR; De Paz Arias R; Llanos EB; Jarque I; Valle MDCF; Tatay AC; De Oteyza JP; Martin EMD; Fernández IP; Martinez RM; Costa MAA; Champ D; Suarez JG; Díaz MG; Ferrer S; Carbonell F; García-Vela JA;
Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600
[TBL] [Abstract][Full Text] [Related]
36. Detection of Minimal Residual Disease in B Cell Acute Lymphoblastic Leukemia Using an Eight-Color Tube with Dried Antibody Reagents.
Bouriche L; Bernot D; Nivaggioni V; Arnoux I; Loosveld M
Cytometry B Clin Cytom; 2019 Mar; 96(2):158-163. PubMed ID: 30698327
[TBL] [Abstract][Full Text] [Related]
37. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
[TBL] [Abstract][Full Text] [Related]
38. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease.
Andersen NS; Donovan JW; Borus JS; Poor CM; Neuberg D; Aster JC; Nadler LM; Freedman AS; Gribben JG
Blood; 1997 Nov; 90(10):4212-21. PubMed ID: 9354694
[TBL] [Abstract][Full Text] [Related]
39. [The Significance of CD319 and CD269 in the Detection of Immunophenotyping and Minimal Residual Disease in Multiple Myeloma Patients].
Chu B; Wang YT; Lu MQ; Shi L; Gao S; Fang LJ; Xiang QQ; Bao L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1195-1202. PubMed ID: 34362502
[TBL] [Abstract][Full Text] [Related]
40. Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy.
Mathis S; Chapuis N; Borgeot J; Maynadié M; Fontenay M; Béné MC; Guy J; Bardet V
Cytometry B Clin Cytom; 2015 Mar; 88(2):101-9. PubMed ID: 25399680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]